TY  - JOUR
TI  - Development of transdermal nanofilm containing fluticasone propionate: In-vitro, in-vivo correlation
AU  - Siddique, Muhammad Irfan
JO  - Pakistan Journal of Pharmaceutical Sciences
JA  - Pak. J. Pharm. Sci.
VL  - 39
IS  - 5
SP  - 1529
EP  - 1537
PY  - 2026
DA  - 2026/05
KW  - Chitosan nanoparticles
KW  - Fluticasone propionate
KW  - In-vivo dermatokinetics
KW  - Psoriasis
DO  - 10.36721/PJPS.2026.39.5.REG.13335.1
AB  - Background: Psoriasis is a chronic inflammatory skin condition affecting approximately 2–3% of the global population. Steroidal therapies are commonly used but are often associated with adverse effects due to high lipophilicity. Objectives: This study aimed to develop a nanoparticle-loaded transdermal film capable of maintaining nanoparticle integrity within the skin. Methods: Fluticasone propionate-loaded chitosan nanoparticles (NPs) were prepared and characterized for particle size, zeta potential, drug loading, entrapment efficiency and morphology using scanning electron microscopy (SEM). The NP-loaded film was further evaluated for physical appearance, thickness and Fourier transform infrared (FTIR) spectra, followed by in vitro and in vivo permeation studies. Results: The nanoparticles exhibited a particle size of approximately 250 nm with a zeta potential of +32.4 ± 1.5 mV, high entrapment efficiency and spherical morphology. In vivo dermatokinetic studies demonstrated prolonged and localized drug release from the nanoparticle-formulated film in epidermal layers compared with films containing free drug. Conclusion: The nanoparticle-loaded transdermal film showed enhanced skin permeation and sustained drug delivery, indicating potential effectiveness in psoriasis management and warranting further investigation.
ER  -